Scancell Holdings plc (LON:SCLP – Get Free Report) passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 12.06 ($0.16) and traded as high as GBX 16 ($0.21). Scancell shares last traded at GBX 15 ($0.20), with a volume of 1,187,988 shares trading hands.
Scancell Stock Performance
The company has a quick ratio of 13.01, a current ratio of 8.63 and a debt-to-equity ratio of 61.41. The firm has a 50-day moving average of GBX 15.79 and a 200 day moving average of GBX 12.06. The stock has a market capitalization of £142.60 million, a P/E ratio of -1,500.00 and a beta of 0.35.
Scancell Company Profile
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer.
Featured Stories
- Five stocks we like better than Scancell
- Roth IRA Calculator: Calculate Your Potential Returns
- How Much Can You Make in Stocks in One Month?
- What is Forex and How Does it Work?
- This Is the Top Large-Cap Stock Insiders Are Buying
- Dividend Payout Ratio Calculator
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
